Influenza
Conditions
Keywords
Influenza, Thiomersal-free influenza split vaccine 2002/2003, Influsplit SSW®/Fluarix™ 2002/2003
Brief summary
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18 years.
Interventions
BIOLOGICALThiomersal free trivalent influenza split vaccine 2002/2003
Single dose, intramuscular injection
BIOLOGICALGlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
Single dose, intramuscular injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects who are capable of being vaccinated and subjects with primary diseases (cardiovascular conditions, metabolic conditions such as diabetes mellitus, respiratory diseases) who are capable of being vaccinated and aged over 18 years who want to be vaccinated against influenza or for whom the doctor considers prophylactic influenza immunisation to be indicated. * The inclusion of individuals who had not been immunised in the 2001/2002 season is preferred. * Written consent to vaccination must be available after the subjects have been briefed on the study in understandable language.
Exclusion criteria
* Use of study or unlicensed medication or administration of a vaccine other than the study vaccine within 30 days preceding vaccination and/or during the study period * Acute disease at the beginning of the study * Acute clinically significant changes in the lungs, cardiovascular system, liver or kidney function, identified by physical examination or laboratory tests * Pregnancy * Women who would like to fall pregnant during the period from the day of vaccination to 1 month thereafter * Known allergic reactions that might have been caused by one or more ingredients of the vaccine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Descriptive comparison of the occurrence, severity and causal relationship to vaccination of solicited local and general symptoms | Within 4 days after vaccination |
| GMT of the haemagglutination-inhibiting antibodies (HIA) and calculation of seroconversion factor, seroconversion rate and seroprotection rate checked against the CHMP criteria. The seroprotection power will be calculated as well. | On Day 21 (± 2) after vaccination |
Secondary
| Measure | Time frame |
|---|---|
| Descriptive comparison of the occurrence and causal relationship to vaccination of unsolicited signs and symptoms | Within 30 days after vaccination |
| Descriptive comparison of the occurrence, severity and causal relationship to vaccination of any serious adverse events (SAEs) | During the entire study period. |
| Investigation of antibody persistence assessed by the criteria of the CHMP. | 11, 19, 27 weeks after vaccination |
Countries
Germany
Outcome results
None listed